Lipogems

Regulatory

Tim AllenApril 10, 2024
0 92

Lipogems Announces Last Patient Enrolled in the U.S. FDA IDE Arise Study for the Treatment of Knee Osteoarthritis

Orthopaedic surgeon, Dr. Cristin Mathew, enrolls a patient in the Lipogems ARISE US FDA IDE Knee OA Study ATLANTA, April 10,…
Read More »
Regulatory

Tim AllenApril 8, 2024
0 237

Lipogems Announces First Patient Enrolled in the Second U.S. FDA IDE Study for the Treatment of Knee Osteoarthritis

Orthopaedic surgeon, Dr. Yogesh Mittal, enrolls the first patient in the ARISE 2 Study for Knee Osteoarthritis ATLANTA, April 8, 2024 /PRNewswire/…
Read More »
Biologics

Josh SandbergOctober 4, 2023
131

U.S. FDA Grants Lipogems® Second IDE Approval For A Clinical Trial On The Treatment For Knee OA

ATLANTA, Oct. 4, 2023 /PRNewswire/ — The U. S. Food and Drug Administration (FDA) has awarded Lipogems another Investigational Device Exemption (IDE) study…
Read More »
Financial

Josh SandbergDecember 26, 2022
165

Lipogems Raises €12.5M ($13.2M) to Accelerate the Expansion in Knee Osteoarthritis

ATLANTA, Dec. 26, 2022 /PRNewswire/ — Lipogems, a clinical stage- global medical technology company that utilizes autologous adipose tissue for therapeutic use in…
Read More »
Biologics

Chris J. StewartJune 10, 2022
274

Lipogems® Receives IDE Approval From The U.S. FDA To Begin A Pivotal Clinical Study On The Safety And Effectiveness Of The Lipogems System For The Treatment of Knee Osteoarthritis

ATLANTA , June 10, 2022 /PRNewswire/ — Lipogems is pleased to announce the unconditional approval by the U.S. Food and Drug Administration (FDA) to…
Read More »
Biologics

Josh SandbergJanuary 14, 2019
1,416

Lipogems Provides Orthopaedic Patients With Another Option To Major Invasive Surgery

ATLANTA, Jan. 14, 2019 /PRNewswire/ — The Lipogems system is leading the way in reparative medicine by providing patients another option to major,…
Read More »
Hospitals

Josh SandbergJuly 6, 2018
2,344

FDA Clears The Way: Lipogems’ Receives FDA Clearance For Microfragmented Adipose Tissue System Utilizing Body’s Own Fat To Support Tissue Repair In Orthopaedic And Arthroscopic Surgeries

NORCROSS, Ga., July 5, 2018 /PRNewswire/ — Lipogems, a leader in medical technologies for orthopaedic physicians, announced U.S. Food and Drug Administration (FDA)…
Read More »

Lipogems

Lipogems Announces Last Patient Enrolled in the U.S. FDA IDE Arise Study for the Treatment of Knee Osteoarthritis

Lipogems Announces First Patient Enrolled in the Second U.S. FDA IDE Study for the Treatment of Knee Osteoarthritis

U.S. FDA Grants Lipogems® Second IDE Approval For A Clinical Trial On The Treatment For Knee OA

Lipogems Raises €12.5M ($13.2M) to Accelerate the Expansion in Knee Osteoarthritis

Lipogems® Receives IDE Approval From The U.S. FDA To Begin A Pivotal Clinical Study On The Safety And Effectiveness Of The Lipogems System For The Treatment of Knee Osteoarthritis

Lipogems Provides Orthopaedic Patients With Another Option To Major Invasive Surgery

FDA Clears The Way: Lipogems’ Receives FDA Clearance For Microfragmented Adipose Tissue System Utilizing Body’s Own Fat To Support Tissue Repair In Orthopaedic And Arthroscopic Surgeries

New Study from HSS Reveals Minimally Invasive Procedure Can Delay Arthritis in Select Patients with Hip Impingement

Four mega mergers helped increase M&A in Q1

Sports Medicine Market Global Forecast 2024-2030, Featuring Key Players Zimmer Biomet, Medtronic, Smith & Nephew, Stryker, Novartis, Johnson & Johnson, Conmed and Surgalign Holdings.